These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20934926)

  • 1. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.
    van Asseldonk DP; Sanderson J; de Boer NK; Sparrow MP; Lémann M; Ansari A; Almer SH; Florin TH; Gearry RB; Mulder CJ; Mantzaris G; van Bodegraven AA;
    Dig Liver Dis; 2011 Apr; 43(4):270-6. PubMed ID: 20934926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How should thiopurine treatment be monitored?--methodological aspects.
    Vikingsson S; Carlsson B; Almer S; Peterson C
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):278-83. PubMed ID: 20544507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of thiopurines in inflammatory bowel disease.
    Frei P; Biedermann L; Nielsen OH; Rogler G
    World J Gastroenterol; 2013 Feb; 19(7):1040-8. PubMed ID: 23467510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease.
    Smith MA; Irving PM; Marinaki AM; Sanderson JD
    Aliment Pharmacol Ther; 2010 Jul; 32(2):119-30. PubMed ID: 20412066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies in the thiopurine treatment of inflammatory bowel disease.
    Almer S
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):267-77. PubMed ID: 20544506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
    Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
    Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
    Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
    Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammatory bowel diseases: conservative therapy].
    Bansky G
    Ther Umsch; 1991 Jul; 48(7):464-70. PubMed ID: 1926006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
    Bradford K; Shih DQ
    World J Gastroenterol; 2011 Oct; 17(37):4166-73. PubMed ID: 22072847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional drug therapy in inflammatory bowel disease.
    Griffin MG; Miner PB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):509-21. PubMed ID: 8809233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.
    Friedman AB; Sparrow MP; Gibson PR
    Int J Rheum Dis; 2014 Feb; 17(2):132-41. PubMed ID: 24618304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine therapy: when to start and when to stop.
    McGovern DP; Travis SP
    Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):219-23. PubMed ID: 12610314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
    Atreya I; Neurath MF
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):23-34. PubMed ID: 19072367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
    Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
    J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.